EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

m6A‐Mediated Stabilization of PRMT9 mRNA by IGF2BP1 Drives Proliferation and Metastasis in Lung Adenocarcinoma

Jinghua Chen iD, Jiahao Yang iD, Zihao Chen iD, Xiangpeng Chu iD

Analytical Cellular Pathology · 2025

DOI: 10.1155/ancp/6050688 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Analytical Cellular Pathology, 2025. Verfasst von Jinghua Chen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Center, Guangzhou Twelfth People's Hospital, No. 1 Tianqiang Road Tianhe District, Guangzhou, 510620, Guangdong, China. Hauptthemen laut MEDLINE: Protein-Arginine N-Methyltransferases, Lung Neoplasms, Adenocarcinoma of Lung, RNA-Binding Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Protein arginine methyltransferase 9 (PRMT9) is dysregulated in various malignancies, particularly in lung adenocarcinoma (LUAD). This study aims to systematically investigate the expression patterns, biological functions, and underlying molecular mechanisms of PRMT9 in LUAD pathogenesis.

Methods

PRMT9 expression was evaluated in paired clinical LUAD specimens and adjacent normal tissues, as well as in normal alveolar epithelial cells versus established lung cancer cell lines. Genetic silencing of PRMT9 was performed in A549 and H1568 cell models to assess its functional impact. Cellular migratory and invasive capacities were quantified using wound healing and Transwell invasion assays. The mechanism of PRMT9 overexpression was explored by examining m6A‐mediated mRNA modification. The role of IGF2BP1 was determined through loss‐of‐function and gain‐of‐function experiments, supplemented with studies under PRMT9‐deficient conditions. Downstream signaling was investigated using specific inhibitors targeting the RAS and MAPK pathways, with in vivo validation in xenograft models.

Results

PRMT9 was significantly upregulated at both transcriptional and translational levels in LUAD tissues and cancer cell lines compared to normal controls. Genetic depletion of PRMT9 substantially impaired cell migration and invasion, and suppressed activation of the RAS/MEK/ERK signaling pathway. The aberrant expression of PRMT9 was mechanistically linked to IGF2BP1‐regulated m6A modification. IGF2BP1 was similarly overexpressed in LUAD specimens and cell models. Knockdown of IGF2BP1 reduced PRMT9 m6A modification, compromised cell viability, migration, and invasion, and attenuated RAS/MEK/ERK signaling. Conversely, IGF2BP1 overexpression enhanced malignant behaviors, effects that were reversed by concurrent PRMT9 knockdown. Mechanistically, PRMT9 overexpression activated the RAS/MAPK signaling axis, and pharmacological inhibition of this pathway mitigated PRMT9‐mediated metastatic progression. In vivo studies confirmed that PRMT9 suppression inhibited tumor growth, which was associated with decreased expression of RAS, pMek1/2, pErk1/2, and Ki67, alongside enhanced caspase‐3 expression.

Conclusion

PRMT9 is overexpressed in LUAD and promotes malignant progression by activating the RAS/MAPK signaling cascade. This aberrant PRMT9 expression is governed by IGF2BP1‐mediated m6A modification. These findings suggest that therapeutic targeting of PRMT9 or the RAS/MAPK signaling axis may represent a promising strategy for LUAD treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein-Arginine N-MethyltransferasesLung NeoplasmsAdenocarcinoma of LungRNA-Binding ProteinsRNA, MessengerAdenosineRNA StabilityHumansCell ProliferationAnimalsGene Expression Regulation, NeoplasticCell MovementCell Line, TumorNeoplasm MetastasisMice, NudeNeoplasm InvasivenessMiceFemale

Stichwörter der Autor:innen

IGF2BP1PRMT9lung adenocarcinomam6A modification

Substanzen

Protein-Arginine N-MethyltransferasesIGF2BP1 protein, humanRNA-Binding ProteinsRNA, MessengerAdenosineN-methyladenosine

Autor:innen und Institutionen

  • Department of Cancer Center, Guangzhou Twelfth People's Hospital, No. 1 Tianqiang Road Tianhe District, Guangzhou, 510620, Guangdong, China.
  • Department of Pulmonary Surgery, Guangdong Provincial People's Hospital, Guangzhou, China, gdghospital.org.cn.

ORCID-Profile: Jinghua Chen, Jiahao Yang, Zihao Chen, Xiangpeng Chu

Zitieren

APA

Chen, J., Yang, J., Chen, Z., & Chu, X. (2025). m6A‐Mediated Stabilization of PRMT9 mRNA by IGF2BP1 Drives Proliferation and Metastasis in Lung Adenocarcinoma. Analytical Cellular Pathology. https://doi.org/10.1155/ancp/6050688

Vancouver

Chen J, Yang J, Chen Z, Chu X. m6A‐Mediated Stabilization of PRMT9 mRNA by IGF2BP1 Drives Proliferation and Metastasis in Lung Adenocarcinoma. Analytical Cellular Pathology. 2025. doi:10.1155/ancp/6050688

BibTeX
@article{Chen2025,
  author = {Chen, Jinghua and Yang, Jiahao and Chen, Zihao and Chu, Xiangpeng},
  title = {m6A‐Mediated Stabilization of PRMT9 mRNA by IGF2BP1 Drives Proliferation and Metastasis in Lung Adenocarcinoma},
  journal = {Analytical Cellular Pathology},
  year = {2025},
  doi = {10.1155/ancp/6050688}
}
Kostenlos starten →